# US 2013/0251640 A1 · Protease degradable polypeptides and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0251640 A1
- Document ID: US20130251640A1
- Status: Published application
- Kind: A1
- Application number: 13/990,866
- Filed: 2011-12-01
- Published: 2013-09-26
- Earliest claimed: 2010-12-01
- Assignees: The Methodist Hospital System
- Inventors: Ching-Hsuan Tung; Wael R. Abd-Elgaliel
- Web page: https://patentgrep.com/patent/US20130251640A1

## CPC

- A61K 49/0045: {the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo}
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/6923: {the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb}
- A61K 49/0039: {Coumarin dyes}
- A61K 49/0056: {Peptides, proteins, polyamino acids}
- A61P 35/00: Antineoplastic agents
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12Q 1/37: involving peptidase or proteinase
- G01N 21/6486: {Measuring fluorescence of biological material, e.g. DNA, RNA, cells (G01N21/6428 takes precedence)}
- G01N 33/533: with fluorescent label
- G01N 33/542: with steric inhibition or signal modification, e.g. fluorescent quenching
- G01N 33/575: for cancer
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided herein are polypeptides that are selectively cleaved by cathepsin E. Also provided are methods of detecting cathepsin E. The methods comprise contacting cathepsin E with the polypeptides provided herein and detecting fluorescence. Further provided are methods of diagnosing cancer or pre-cancerous conditions in a subject. Also provided herein is a multilayered nanoparticle or a composition comprising the multilayer nanoparticle, wherein the multilayered nanoparticle comprises a negatively charged nanoparticle core or capsule coated with alternating positive and negative layers. Optionally, the positive layer comprises a positively charged protease degradable polypeptide. Optionally, the negative layer comprises a negatively charged therapeutic agent or a therapeutic agent and a means for providing the agent with a negative charge. For example, optionally, the therapeutic agent is linked to a negatively charged polymer. Further provided are methods of treating or preventing a disease characterized by expression of a protease in a subject using the nanoparticle.

## Claims

### Claim 1

A polypeptide comprising:
(a) a fluorescent donor moiety;
(b) an energy acceptor moiety;
(c) an amino acid sequence comprising a Leucine-Proline or a Leucine-X-Proline linkage at a scissile bond of the polypeptide, wherein X is an amino acid residue, wherein the amino acid sequence comprising the Leucine-Proline or Leucine-X-Proline linkage is between the fluorescent donor moiety and the energy acceptor moiety, wherein the scissile bond is selectively cleaved by cathepsin E, and wherein cleavage of the scissile bond results in fluorescence.

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The polypeptide of claim 1, wherein the fluorescent donor moiety and the energy acceptor moiety are the same moiety.

### Claim 7 (depends on 1)

The polypeptide of claim 1, wherein the amino acid sequence is selected from the group consisting of Ala-Gly-Phe-Ser-Leu-Pro-Ala-Lys-Arg (SEQ ID NO:1), SEQ ID NO:1 with up to two conservative amino acid substitutions, Phe-Ser-Leu-Pro-Ala (SEQ ID NO:2), SEQ ID NO:2 with up to two conservative amino acid substitutions, Phe-Ser-Leu-X-Pro-Ala (SEQ ID NO:3), SEQ ID NO:3 with up to two conservative amino acid substitutions, Ala-Gly-Phe-Ser-Leu-Gly-Pro-Lys-Arg (SEQ ID NO:4), and SEQ ID NO:4 with up to two conservative amino acid substitutions.

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10 (depends on 7)

The polypeptide of claim 7, wherein the fluorescent donor moiety or the energy acceptor moiety are linked to the polypeptide by a spacer.

### Claim 11 (depends on 7)

The polypeptide of claim 7, wherein the fluorescent donor moiety or energy acceptor moiety is covalently linked to the N-terminal Ala of SEQ ID NO:1, is covalently linked to the Lys of SEQ ID NO:1, is covalently linked to the Ala of SEQ ID NO:4 or SEQ ID NO:4 with up to two conservative amino acid substitutions, or is covalently linked to the Lys of SEQ ID NO:4 or SEQ ID NO:4 with up to two conservative amino acid substitutions.

### Claim 12

(canceled)

### Claim 13 (depends on 7)

The polypeptide of claim 7, wherein the amino acid sequence comprises SEQ ID NO:1.

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18 (depends on 7)

The polypeptide of claim 7, wherein the amino acid sequence comprises SEQ ID NO:4.

### Claim 19 (depends on 1)

A method of detecting cathepsin E comprising:
(a) contacting the cathepsin E with the polypeptide of claim 1;
(b) detecting fluorescence, wherein fluorescence indicates the presence of cathepsin E.

### Claim 20 (depends on 19)

The method of claim 19, wherein the contacting step is performed in vivo.

### Claim 21 (depends on 19)

The method of claim 19, wherein the contacting step is performed in vitro.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26 (depends on 19)

The method of claim 19, wherein the fluorescent donor moiety and the energy acceptor moiety are the same moiety.

### Claim 27 (depends on 19)

The method of claim 19, wherein the amino acid sequence of the polypeptide is selected from the group consisting of Ala-Gly-Phe-Ser-Leu-Pro-Ala-Lys-Arg (SEQ ID NO:1), SEQ ID NO:1 with up to two conservative amino acid substitutions, Phe-Ser-Leu-Pro-Ala (SEQ ID NO:2), SEQ ID NO:2 with up to two conservative amino acid substitutions, Phe-Ser-Leu-X-Pro-Ala (SEQ ID NO:3), SEQ ID NO:3 with up to two conservative amino acid substitutions, Ala-Gly-Phe-Ser-Leu-Gly-Pro-Lys-Arg (SEQ ID NO:4), and SEQ ID NO:4 with up to two conservative amino acid substitutions.

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30 (depends on 27)

The method of claim 27, wherein the fluorescent donor moiety or the energy acceptor moiety are linked to the polypeptide by a spacer.

### Claim 31 (depends on 27)

The method of claim 27, wherein the fluorescent donor moiety or the energy acceptor moiety is covalently linked to the N-terminal Ala of SEQ ID NO:1 or SEQ ID NO:1 with up to two conservative amino acid substitutions, is covalently linked to the Lys of SEQ ID NO:1 or SEQ ID NO:1 with up to two conservative amino acid substitutions, is covalently linked to the Ala of SEQ ID NO:4 or SEQ ID NO:4 with up to two conservative amino acid substitutions, or is covalently linked to the Lys of SEQ ID NO:4 or SEQ ID NO:4 with up to two conservative amino acid substitutions.

### Claim 32

(canceled)

### Claim 33 (depends on 27)

The method of claim 27, wherein the amino acid sequence comprises SEQ ID NO:1.

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38 (depends on 27)

The method of claim 27, wherein the amino acid sequence comprises SEQ ID NO:4.

### Claim 39 (depends on 19)

The method of claim 19, wherein the cathepsin E is in a cell.

### Claim 40 (depends on 39)

The method of claim 39, wherein the cell is a cancer cell.

### Claim 41

(canceled)

### Claim 42 (depends on 1)

A method of diagnosing cancer or detecting a pre-cancerous condition in a subject, the method comprising:
(a) contacting a cell of the subject with the polypeptide of claim 1;
(b) detecting fluorescence in the cell above background, wherein fluorescence in the subject above background indicates the subject has cancer or a pre-cancerous condition.

### Claim 43 (depends on 42)

The method of claim 42, wherein the contacting step is performed in vivo.

### Claim 44 (depends on 42)

The method of claim 42, wherein the contacting step is performed in vitro.

### Claim 45

(canceled)

### Claim 46

(canceled)

### Claim 47

(canceled)

### Claim 48

(canceled)

### Claim 49 (depends on 42)

The method of claim 42, wherein the fluorescent donor moiety and the energy acceptor moiety are the same moiety.

### Claim 50 (depends on 42)

The method of claim 42, wherein the amino acid sequence of the polypeptide is selected from the group consisting of Ala-Gly-Phe-Ser-Leu-Pro-Ala-Lys-Arg (SEQ ID NO:1), SEQ ID NO:1 with up to two conservative amino acid substitutions, Phe-Ser-Leu-Pro-Ala (SEQ ID NO:2), SEQ ID NO:2 with up to two conservative amino acid substitutions, Phe-Ser-Leu-X-Pro-Ala (SEQ ID NO:3), SEQ ID NO:3 with up to two conservative amino acid substitutions, Ala-Gly-Phe-Ser-Leu-Gly-Pro-Lys-Arg (SEQ ID NO:4), and SEQ ID NO:4 with up to two conservative amino acid substitutions.

### Claim 51

(canceled)

### Claim 52

(canceled)

### Claim 53 (depends on 50)

The method of claim 50, wherein the fluorescent donor moiety or the energy acceptor moiety are linked to the polypeptide by a spacer.

### Claim 54 (depends on 50)

The method of claim 50, wherein the fluorescent donor moiety or the energy acceptor moiety is covalently linked to the N-terminal Ala of SEQ ID NO:1 or SEQ ID NO:1 with up to two conservative amino acid substitutions, is covalently linked to the Lys of SEQ ID NO:1 or SEQ ID NO:1 with up to two conservative amino acid substitutions, is covalently linked to the Ala of SEQ ID NO:4 or SEQ ID NO:4 with up to two conservative amino acid substitutions, or is covalently linked to the Lys of SEQ ID NO:4 or SEQ ID NO:4 with up to two conservative amino acid substitutions.

### Claim 55

(canceled)

### Claim 56 (depends on 50)

The method of claim 50, wherein the amino acid sequence comprises SEQ ID NO:1.

### Claim 57

(canceled)

### Claim 58

(canceled)

### Claim 59

(canceled)

### Claim 60

(canceled)

### Claim 61 (depends on 50)

The method of claim 50, wherein the amino acid sequence comprises SEQ ID NO:4.

### Claim 62 (depends on 42)

The method of claim 42, wherein the cancer or pre-cancerous condition are selected from the group consisting of a pancreatic ductal adenocarcinoma, a cervical adenocarcinoma, a gastric adenocarcinoma, a prostate cancer, a colorectal cancer, a lung carcinoma, a breast cancer, an andenoendocrine carcinoma, a neuroendocrine positive tumor, and pre-cancerous conditions thereof.

### Claim 63 (depends on 42)

The method of claim 42, wherein the subject has been previously treated for cancer.

### Claim 64

(canceled)

### Claim 65

(canceled)

### Claim 66

(canceled)

### Claim 67

(canceled)

### Claim 68

(canceled)

### Claim 69

(canceled)

### Claim 70

(canceled)

### Claim 71

(canceled)

### Claim 72

(canceled)

### Claim 73

(canceled)

### Claim 74

(canceled)

### Claim 75

(canceled)

### Claim 76

(canceled)

### Claim 77

(canceled)

### Claim 78

(canceled)

### Claim 79

(canceled)

### Claim 80

(canceled)

### Claim 81

(canceled)

### Claim 82

(canceled)

### Claim 83 (depends on 1)

A method of monitoring the effectiveness of a cancer treatment in a subject being treated for cancer, the method comprising:
(a) contacting a cell of the subject at various time points with the polypeptide of claim 1; and
(b) detecting a level of fluorescence in the cell, wherein a decreasing level of fluorescence indicating that the treatment is effective, and wherein an unchanged or increasing level of fluorescence indicating that the treatment is ineffective.

### Claim 84 (depends on 83)

The method of claim 83, wherein the contacting step is performed in vivo.

### Claim 85 (depends on 83)

The method of claim 83, wherein the contacting step is performed in vitro.

### Claim 86

(canceled)

### Claim 87

(canceled)

### Claim 88

(canceled)

### Claim 89

(canceled)

### Claim 90 (depends on 83)

The method of claim 83, wherein the fluorescent donor moiety and the energy acceptor moiety are the same moiety.

### Claim 91 (depends on 83)

The method of claim 83, wherein the amino acid sequence of the polypeptide is selected from the group consisting of Ala-Gly-Phe-Ser-Leu-Pro-Ala-Lys-Arg (SEQ ID NO:1), SEQ ID NO:1 with up to two conservative amino acid substitutions, Phe-Ser-Leu-Pro-Ala (SEQ ID NO:2), SEQ ID NO:2 with up to two conservative amino acid substitutions, Phe-Ser-Leu-X-Pro-Ala (SEQ ID NO:3), SEQ ID NO:3 with up to two conservative amino acid substitutions, Ala-Gly-Phe-Ser-Leu-Gly-Pro-Lys-Arg (SEQ ID NO:4), and SEQ ID NO:4 with up to two conservative amino acid substitutions.

### Claim 92

(canceled)

### Claim 93

(canceled)

### Claim 94 (depends on 91)

The method of claim 91, wherein the fluorescent donor moiety or the energy acceptor moiety are linked to the polypeptide by a spacer.

### Claim 95 (depends on 91)

The method of claim 91, wherein the fluorescent donor moiety or the energy acceptor moiety is covalently linked to the N-terminal Ala of SEQ ID NO:1 or SEQ ID NO:1 with up to two conservative amino acid substitutions, is covalently linked to the Lys of SEQ ID NO:1 or SEQ ID NO:1 with up to two conservative amino acid substitutions, is covalently linked to the Ala of SEQ ID NO:4 or SEQ ID NO:4 with up to two conservative amino acid substitutions, or is covalently linked to the Lys of SEQ ID NO:4 or SEQ ID NO:4 with up to two conservative amino acid substitutions.

### Claim 96

(canceled)

### Claim 97 (depends on 91)

The method of claim 91, wherein the amino acid sequence comprises SEQ ID NO:1.

### Claim 98

(canceled)

### Claim 99

(canceled)

### Claim 100

(canceled)

### Claim 101

(canceled)

### Claim 102 (depends on 91)

The method of claim 91, wherein the amino acid sequence comprises SEQ ID NO:4.

### Claim 103 (depends on 83)

The method of claim 83, wherein the cancer is selected from the group consisting of a pancreatic ductal adenocarcinoma, a cervical adenocarcinoma, a gastric adenocarcinoma, a prostate cancer, a colorectal cancer, a lung carcinoma, a breast cancer, an adenoendocrine carcinoma, and a neuroendocrine positive tumor.
